AGC announces acquisition of commercial facility in Colorado, U.S.
AGC Biologics, a leading biopharmaceutical CDMO (Contract Development & Manufacturing Organization), has reportedly purchased a commercial manufacturing facility. This state-of-the-art facility, owned previously by AstraZeneca, is located in Boulder County, Colorado, United States. The company, which employs around 1,000 employees across the globe, is committed to offering high-quality services to its partners and clients.
The facility will significantly offer additional capacity to AGC as well as increase the production scale. The full-scale operation & manufacturing process of the facility is expected to start by April 2021.
This large-scale biopharmaceutical facility in Colorado houses 2 stainless steel bioreactors for mammalian cells, with a total volume of 20,000 liters. It expands across an area of 20 acres, generating high opportunities for facility expansions in the future. It also includes an area for over 4 additional bioreactors of 20,000 liters capacity. High antibody titer processes and large-scale commercial production can be efficiently carried out in this cost-effective and automated facility.
AGC is accelerating the expansion of its customer portfolio, including commercial projects and a higher late phase ratio, and advancing the ongoing projects to the commercial phase. The company will significantly cater to various commercial demand through this addition to the facility network.
Apart from the recent acquisition of Colorado facility, the company is planning to complete facility expansion projects at the facilities in Seattle, Copenhagen, & Chiba by the beginning of 2021.
As per the statement made by Patricio Massera, chief executive officer of AGC Biologics, the large-scale expansion initiative of the company will be assisted by the recent addition of the Colorado facility. This highlights its aim to continuously serve the demand for the mammalian projects from its customers. Within its dynamic global company, the recently acquired facility will allow the continual advancement of the development, commercial, and manufacturing functions.
Source credit:
About Author
Pranali Mehta
Pranali Mehta boasts of over three years of experience as a content writer. Having completed her graduation in chemical engineering, she worked as safety & environment associate in a chemical company for a year. Harnessing her passion for writing however, Pranali decided to pursue content developmen...
Read More